Novo Nordisk A/S — Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2022. The filing is an annual Form 20-F, not a standalone fourth-quarter filing. Financial statements are prepared under IFRS as issued by the IASB and reported in DKK. The filing incorporates selected pages of the 2022 Annual Report, including the consolidated financial statements and management discussion.
Business context
Novo Nordisk is a global pharmaceutical company focused primarily on Diabetes and Obesity care, with a Rare disease segment. It employed more than 50,000 people in 80 countries and marketed products in approximately 170 countries. Diabetes and Obesity care represented more than 80% of sales.
Key products included Ozempic, Rybelsus, Wegovy, Saxenda, insulin products, haemophilia therapies and growth hormone products. Ozempic generated DKK 59.8 billion of global sales in 2022.
Financial performance and liquidity
| Metric | 2022 information disclosed in the filing |
|---|---|
| Revenue and net profit | The provided filing text does not state consolidated revenue, operating profit, net profit or earnings per share. The amounts are included in the incorporated Annual Report financial statements. |
| Obesity care sales | DKK 16.864 billion, compared with DKK 8.400 billion in 2021. |
| Victoza sales | DKK 12.322 billion, compared with DKK 15.054 billion in 2021. |
| U.S. sales rebate provisions | Group provision for sales rebates and discounts was DKK 69.499 billion at December 31, 2022, a significant portion relating to the United States. |
| Cash flow and free cash flow | The filing refers to the Annual Report cash flow statement but the provided text does not state consolidated operating cash flow or free cash flow. |
| Debt and liquidity | Specific current and non-current debt balances are not provided in the filing text. Management stated that financial resources were sufficient to meet requirements for at least the next 12 months. |
| Capital expenditure | Specific total 2022 capital expenditure is not provided. Major projects included DKK 16.5 billion for Kalundborg API facilities, DKK 5.4 billion for Bagsværd clinical manufacturing, and other capacity investments. |
Material changes versus the prior comparable period
- Obesity care sales approximately doubled to DKK 16.864 billion from DKK 8.400 billion, driven primarily by Saxenda and the rollout of Wegovy.
- Victoza sales declined to DKK 12.322 billion from DKK 15.054 billion, reflecting competitive and patent-related pressures.
- Demand for GLP-1 products, particularly Ozempic, exceeded available manufacturing capacity, resulting in periodic supply constraints and drug-shortage notifications.
- All Wegovy dose strengths became available in the United States in December 2022 after a contract manufacturer disruption that began in 2021.
- Novo Nordisk completed the approximately USD 1.1 billion acquisition of Forma Therapeutics in October 2022. Forma’s assets represented approximately 0.4% of consolidated assets and approximately 0.0% of consolidated net profit for 2022.
- The company repurchased 28.4 million B shares under its 2022 program at an average price of DKK 792.11 per share. A DKK 24 billion program initiated in 2022 was completed in February 2023.
- China’s Volume Based Procurement program materially affected insulin prices and volumes and reduced sales in China. The impact was expected to continue into the first half of 2023.
Outlook, commentary and risks
- Periodic supply constraints were expected to continue during 2023 while manufacturing capacity was expanded.
- Average U.S. prices after rebates were expected to decline further in 2023, particularly for insulin. Market access was expected to remain broadly similar to 2022.
- Management expected research and development spending to grow in line with or slightly above sales growth, with the R&D-to-sales ratio expected to rise modestly from approximately 12–13%.
- Key commercial risks include payer and pharmacy benefit manager rebate pressure, insulin competition and biosimilars, pricing controls, China’s procurement program, and potential loss of patent protection. Compound patents for Victoza and Saxenda expire in important markets in 2023, while generic Victoza launches in the United States were not expected before June 2024 under disclosed settlements.
- Operational risks include manufacturing capacity limitations, supply-chain disruption, product recalls, raw-material or energy interruptions and cybersecurity incidents.
- Development and regulatory risks affect the company’s extensive late-stage pipeline. Projects may be delayed, fail clinical testing or fail to obtain regulatory approval.
- Legal and regulatory exposure includes U.S. litigation concerning the company’s 340B pharmacy policy and uncertainty regarding U.S. sales rebate estimates. The 340B issue was identified as a critical audit matter.
- Sales in Russia and Ukraine were each limited in aggregate, with combined sales constituting less than 1% of global sales in 2022. Novo Nordisk continued supplying essential medicines while suspending further marketing and clinical investments in Russia.
Controls, audit and unusual items
Management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2022. Deloitte issued an unqualified audit opinion on the financial statements and internal controls. Forma Therapeutics was excluded from management’s internal-control assessment because it was acquired on October 14, 2022.
The filing identifies U.S. sales rebates, including provisions related to the 340B program, as the critical audit matter because of significant estimation uncertainty involving legal interpretations, payer arrangements, claims data, channel mix and inventory levels.
Novo Nordisk disclosed limited Iran-related activities conducted by subsidiaries. Gross revenue from transactions with Iranian government-owned or controlled entities was not more than 1% of Group sales, and estimated net profit was de minimis relative to Group net profit.
Facts investors should verify
- Retrieve the incorporated Annual Report pages 54–85 to verify consolidated revenue, operating profit, net profit, margins, cash flow, debt, cash balances, dividends and capital expenditure.
- Assess whether manufacturing expansions are sufficient to address continuing Ozempic, Wegovy and other product supply constraints.
- Evaluate the sensitivity of revenue and earnings to U.S. rebates, the 340B litigation, Inflation Reduction Act implementation and payer negotiations.
- Review patent expiry timelines and potential generic or biosimilar competition for Victoza, Saxenda, insulin products and semaglutide.
- Monitor China’s Volume Based Procurement impact on insulin pricing and volume during 2023.
- Review the accounting and integration effects of the Forma Therapeutics acquisition and the company’s late-stage pipeline execution risks.